company background image
CMMB logo

Chemomab Therapeutics NasdaqCM:CMMB Stock Report

Last Price

US$0.77

Market Cap

US$10.9m

7D

-2.4%

1Y

-52.2%

Updated

27 Mar, 2024

Data

Company Financials +

Chemomab Therapeutics Ltd.

NasdaqCM:CMMB Stock Report

Market Cap: US$10.9m

CMMB Stock Overview

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases.

CMMB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Chemomab Therapeutics Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Chemomab Therapeutics
Historical stock prices
Current Share PriceUS$0.77
52 Week HighUS$1.89
52 Week LowUS$0.42
Beta-0.098
1 Month Change14.93%
3 Month Change45.28%
1 Year Change-52.17%
3 Year Change-97.32%
5 Year Changen/a
Change since IPO-98.69%

Recent News & Updates

Recent updates

Will Chemomab Therapeutics (NASDAQ:CMMB) Spend Its Cash Wisely?

Jan 10
Will Chemomab Therapeutics (NASDAQ:CMMB) Spend Its Cash Wisely?

Chemomab Therapeutics (NASDAQ:CMMB) Is In A Good Position To Deliver On Growth Plans

Sep 19
Chemomab Therapeutics (NASDAQ:CMMB) Is In A Good Position To Deliver On Growth Plans

Chemomab Therapeutics - ADR GAAP EPS of -$0.027

Aug 12

Chemomab Therapeutics: Pioneering Anti-CCL24 MAb For Fibrotic Diseases

Dec 03

Shareholder Returns

CMMBUS BiotechsUS Market
7D-2.4%0.9%0.4%
1Y-52.2%10.3%28.8%

Return vs Industry: CMMB underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: CMMB underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is CMMB's price volatile compared to industry and market?
CMMB volatility
CMMB Average Weekly Movement8.9%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: CMMB's share price has been volatile over the past 3 months.

Volatility Over Time: CMMB's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2011n/aAdi Georgehttps://www.chemomab.com

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company’s lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd.

Chemomab Therapeutics Ltd. Fundamentals Summary

How do Chemomab Therapeutics's earnings and revenue compare to its market cap?
CMMB fundamental statistics
Market capUS$10.94m
Earnings (TTM)-US$24.22m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CMMB income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$24.22m
Earnings-US$24.22m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.71
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did CMMB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.